301907 VO Development of novel cancer immunotherapies (2022W)
from target identification through target validation to clinical trials
Labels
MIXED
Registration/Deregistration
Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
Details
Language: English
Examination dates
- Monday 09.01.2023 08:30 - 18:00 BZB/Seminarraum 3, 6.Ebene 6.105, Dr.-Bohrgasse 9, 1030 Wien
- Monday 16.01.2023 17:30 - 19:30 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
- Monday 27.02.2023 10:00 - 12:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
- Monday 27.03.2023 17:30 - 19:30 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
Lecturers
Classes (iCal) - next class is marked with N
Vorlesungen digital über moodle
Minisymposium: 9.1.2023 - SR 4/6.105 - BZB, Dr.Bohrgasse 9/6.Stock. 1030 Wien. - Anmeldung über Prüfungstermin am 9.1.
- Monday 31.10. 10:00 - 11:30 Digital
- Monday 07.11. 10:00 - 11:30 Digital
- Monday 21.11. 10:00 - 11:30 Digital
- Monday 28.11. 10:00 - 11:30 Digital
- Monday 05.12. 10:00 - 11:30 Digital
- Monday 12.12. 10:00 - 11:30 Digital
- Monday 19.12. 10:00 - 11:30 Digital
Information
Aims, contents and method of the course
Assessment and permitted materials
written exam
Minimum requirements and assessment criteria
100-87%: Sehr Gut ( I ); 87,99-75%: Gut (2); 74,99-62%: Befriedigend (3); 6 I ,99-50%: Genügend (4); < 50%: Nicht Genügend (5)
Examination topics
Reading list
Association in the course directory
MMB IV-2,MMB W-2, MMB IV., MMEI II-3.2,MMEI III, WZB
Last modified: We 12.07.2023 13:47
(1) give an overview on current therapies: their potential, their risks and where they currently fail: description of different therapy modalities: Antibodies (check point inhibitors, protacs, T cell engagers , neutralizing Antibodies) and small molecule therapies (inhibitors and agonists)
(2) description on how cancer imrnunotherapy targets are being discovered: available methods for target screening and how to validate them
(3) description how to validate the targets
(4) explain why biomarker research is important for the success oftherapies
(5) describe the different stages of clinical trials